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We conducted a retrospective cross-sectional study to estimate the humanistic and economic burden associated with depression
and anxiety among adults with comorbid diabetes and hypertension. Pooled data from the 2013 and 2015 Medical Expenditure
Panel Survey were used to include adults (≥18 years old) who were alive and diagnosed with both diabetes and hypertension
during the observation period. We assessed the humanistic burden with health-related quality of life (HRQoL) and economic
burden with the total annual healthcare expenditures. Depending on the presence/absence of depression and anxiety, the study
sample was divided into four groups (i.e., no depression/anxiety, depression only, anxiety only, and depression and anxiety).
Multivariable regression analyses were used to evaluate the associations between the depression/anxiety categories and disease
burden measures. The incremental burden associated with depression and/or anxiety was estimated with the counterfactual
recycled prediction. Of the 4560 adults with comorbid diabetes and hypertension, 13.2% reported depression only, 8.7%
reported anxiety only, and 7.7% reported both. Results from adjusted analyses indicated that the presence/absence of depression
and anxiety was associated with signiﬁcantly poorer HRQoL, especially on the mental component. Having either depression or
anxiety corresponded to reduced mental component summary scores by more than four points. The reduction was as high as
10.35 points when both conditions occurred. Comparing to adults without depression or anxiety, the per-capital incremental
annual healthcare expenditures were $4607 for the depression group, $2481 for the anxiety group, and $8709 for adults with
both conditions. Furthermore, adults with depression and anxiety were 58% more likely to spend at least 10% of annual
household income on healthcare as compared to those with neither the conditions. Our results highlight the needs for
integrating cost-eﬀective mental health services into diabetes management to improve the HRQoL and reduce healthcare costs
for adults with comorbid diabetes and hypertension.

1. Introduction
Comorbid chronic conditions can post an enormous
challenge in diabetes care. Hypertension is one of the most
common comorbid conditions due to a considerable overlap
of risk factors [1]. Approximately 75% of individuals diagnosed with diabetes have concomitant hypertension, representing nearly 23 million adults in the United States (US)
[1, 2]. Individuals with multiple chronic conditions usually

have impaired mental health [3]. Like many other chronic
conditions, diabetes and hypertension are independently
associated with a higher prevalence of mental conditions,
particularly depression and anxiety [4]. The prevalence of
depression and anxiety ranges from 15% to 35% among
individuals with diabetes [5, 6] and 22% to 56% among those
with hypertension [7, 8].
The presence of depression and/or anxiety can impose
substantial disease burdens on adults with comorbid diabetes
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and hypertension as they ranked amongst the top ten causes
of disease burden in the 2013 Global Burden of Disease Study
[9]. The presence of either the condition can complicate the
course of diabetes and hypertension by causing increased
inﬂammation, unhealthy lifestyles, and poor adherence to
treatments [10]. Furthermore, depression and anxiety can
lead to signiﬁcant functional impairments, resulting in poor
quality of life [11, 12]. Results from several observational
studies have indicated that depression and anxiety manifest
themselves in multiple facets of the quality of life for individuals with diabetes, including functional, cognitive, and emotional domains [13–15].
The impairment in quality of life also represents a considerable economic burden on patients, their family members,
and the whole healthcare system due to high use of healthcare services. Diabetes is one of the most expensive chronic
conditions in the US, with an estimated medical expenditure
of $237 billion in 2017 [16]. Based on the ﬁnding of a recent
study, the national burden of comorbid diabetes and hypertension could exceed $350 billion [17]. Depression and
anxiety have been indicated with higher risks of diabetes
complications and heart diseases, leading to excess costs from
more physician oﬃce visits, emergency room or inpatient
admissions, and prescription consumption [18, 19].
Depression, anxiety, diabetes, and hypertension are
closely linked and aﬀect a substantial proportion of the US
population. Individuals that carry more than one, or even
all four conditions, face unique challenges regarding access
to the healthcare resources and the emotional state to achieve
optimal treatment goals. Evaluating the burden of mental
comorbidities has indispensable roles in achieving these
goals because it helps direct resource allocation for policymakers. Like diabetes and hypertension, depression and
anxiety also have substantial overlap in occurrence [20].
Although previous studies have evaluated the impact of
depression and anxiety on individuals with diabetes or
hypertension separately, no study has comprehensively
quantiﬁed the eﬀect of either of the condition alone. Furthermore, researchers have reported that treating comorbid depression and anxiety could be more challenging
than managing each condition alone [21]. Research attention on comorbid depression and anxiety is therefore warranted to help understand the unmet needs in providing
care to patients with such complex conditions. Therefore,
the objective of this study is to estimate the humanistic
and economic burden of depression and/or anxiety among
adults with comorbid diabetes and hypertension.

2. Materials and Methods
2.1. Study Design. This study utilized a retrospective crosssectional design.
2.2. Data Source. We pooled data from the 2013 and 2015
Medical Expenditure Panel Survey (MEPS). The MEPS is a
nationally representative survey of noninstitutionalized
adults. It collects information on demographics and various
facets of healthcare, including medical conditions, access to
care, health-related quality of life (HRQoL), and medical
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expenditures. The MEPS employs a panel design, in which
participants were followed for two years. As recommended
by MEPS, we utilized alternate years to avoid duplicate observations of the same participant [22].
2.3. Study Sample. Our descriptive sample consisted of 4560
adults (aged 18 or older) who were alive and diagnosed with
both diabetes and hypertension during the study period
(2013 and 2015). Diabetes and hypertension were identiﬁed
from the full-year consolidated ﬁle based on queries
regarding the diagnosis of speciﬁc conditions or medical
condition ﬁles using the clinical classiﬁcation codes (49–50
for diabetes, 98–99 for hypertension). These conditions
were reported by households, recorded by professional
coders, and then converted into clinical classiﬁcation codes
by MEPS researchers. Because the MEPS only collects data
on HRQoL through self-administered questionnaires
(SAQ), we further restricted our sample to adults who were
eligible for SAQ to analyze humanistic outcomes. For economic outcomes, the analytic cohort only included adults
with positive expenditures.
2.4. Dependent Variables
2.4.1. Humanistic Outcome: Health-Related Quality of Life
(HRQoL). MEPS measures HRQoL with the 12-item shortform health survey version 2 (SF-12v2). The SF-12v2 is a
widely used generic measure for HRQoL in health services
research. MEPS researchers combined, scored, and weighted
the responses to create physical component summary (PCS)
and mental component summary (MCS) scores. The scores
range from 0 to 100, with higher scores indicating better
HRQoL related to physical and/or mental health [23].
2.4.2. Economic Outcomes: Total Annual Healthcare
Expenditures. The MEPS is considered as the most complete
source of data on healthcare expenditures. Healthcare expenditures are measured as any payment to healthcare providers
(i.e., hospitals, outpatient facilities, private practices, and
long-term care facilities) for healthcare services (i.e., inpatient, outpatient, prescription, dental, vision, and home
health services). Payers include patients or their families
paying for a service out-of-pocket as well as third-party
payers (Medicare, Medicaid, private insurance, Veterans
Administration, Tricare, HMOs, etc.). Total annual perperson healthcare expenditures were calculated as the sum
of all medical payments from all payers. We conducted separate analyses on total expenditures, those paid by third parties
and out-of-pocket (OOP) spending from patients. Thirdparty expenditures were calculated as the diﬀerence between
total expenditures and OOP spending. All expenditures were
adjusted to 2015 US dollars using the consumer price index
for medical services from the Bureau of Labor Statistics.
2.4.3. Economic Outcomes: OOP Spending Burden. The
economic burden from OOP spending was measured as the
percentage of annual household income spent on healthcare
as OOP payments [24]. We used a conventional cut-oﬀ of
10% to deﬁne high burden [25].
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2.5. Key Independent Variable
2.5.1. Depression/Anxiety Categories. We identiﬁed depression and anxiety from the medical condition ﬁles using the
clinical classiﬁcation code of “657” and “651.” A variable with
four categories (depression and anxiety, depression only,
anxiety only, and no depression/anxiety) was created based
on the presence/absence of depression and anxiety.
2.6. Other Independent Variables. We selected other independent variables under the guidance of the Andersen’s behavioral model [26], in which an individual’s use of healthcare
services and associated outcomes is considered as a function
of predisposing factors, enabling factors, need factors,
personal health practices, and external environment. We
included sex (male/female), race/ethnicity (Whites/AfricanAmerican/Latino/other racial minorities), and age (18–39/
40–54/55–64/65–74/75+) as predisposing factors. Enabling
factors were comprised of marital status (married/not
married), education (less than high school/high school/more
than high school), family poverty status (poor/near poor/
middle income/high income), health insurance (private/public/uninsured), and prescription insurance status (yes/no).
Need factors included having a chronic condition (yes/no)
other than diabetes and hypertension from a list of eight conditions (asthma, arthritis, cancer, chronic obstructive pulmonary disease, heart disease, and stroke), perceived physical
and mental health status (excellent/very good, good, and
fair/poor), and pain interference (mild/no, moderate, and a
lot/extreme). Personal health practice factors included
obesity (yes/no), smoking status (current smoker/others),
and physical activities (ﬁve times or more/week, less than ﬁve
times/week). We also used geographic region (northeast/
midwest/south/west) of residency to account for variations
due to the external environment.
2.7. Statistical Analyses. We used chi-square tests to determine statistically signiﬁcant diﬀerences across study groups
for categorical variables and Student’s independent t-tests
for continuous variables. Multivariable regression analyses
were used to examine the association between the depression/anxiety categories and disease burden measures. Ordinary least square regressions were employed to analyze
MCS and PCS scores. Logistic regressions were used for
binary outcomes such as OOP spending burden. To overcome common challenges associated with modeling expenditures (e.g., high positive skewness and heteroscedasticity), we
used generalized linear models with a log link function and
gamma family distribution for expenditure outcomes [27].
To estimate excess healthcare expenditures contributed
by depression and/or anxiety, we utilized counterfactual
recycled prediction. This technique is preferable because, by
creating counterfactual scenarios, it allows for adjustment
for diﬀerences in characteristics across all groups (i.e.,
depression and anxiety, depression only, anxiety only, and
neither depression nor anxiety) [28]. To account for the
complex survey design of the MEPS, we utilized the survey
procedures in the statistical analysis software (SAS) version
9.4 (Cary, NC, USA) and STATA 14. As recommended by
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MEPS researchers, we computed annualized weights by
dividing personal weights by the number of years pooled
(two, in our study) [29]. Annualized SAQ weights were used
for analyzing MCS and PCS.

3. Results
3.1. Description of Study Sample. The study sample was
almost evenly female (50.1%) and male (49.9%). The majority were white (62%), aged greater than 55 (76%), with multimorbidity (73%), and adults who had at least a high school
education (80%). Twenty-seven percent of individuals
considered themselves as having excellent or very good
physical health while 48% reported having excellent or very
good mental health (Table 1).
Within our sample, approximately one-ﬁfth had either
depression (13.2%) or anxiety (8.7%), and 7.7% had both
conditions. We observed signiﬁcant diﬀerences in the prevalence of depression and/or anxiety across all predisposing
factors, enabling factors, need factors, personal health
practices, and external environment with the exception for
education. For example, females with comorbid diabetes
and hypertension reported a signiﬁcantly higher rate of
depression and anxiety, either alone or together, as compared to their male counterparts. Similar patterns were
observed for adults with public insurances relative to private
insurances or no insurance, adults reporting multimorbidity
in addition to diabetes and hypertension versus those without additional chronic conditions, and adults with severe
pain interference as compared to those with mild or no pain
interference (Table 1).
3.2. Humanistic Outcomes: Physical and Mental Component
Summary Scores (PCS and MCS). Adults with depression
and/or anxiety reported signiﬁcant lower health scores, both
physically and mentally, as compared to those with neither
the condition. Across the four groups, adults with both
depression and anxiety reported the lowest MCS scores while
those with depression had the lowest PCS scores (Table 1).
However, after adjusting for all other covariates, we only
observed signiﬁcant diﬀerences in MCS scores. Results from
adjusted analyses indicated that, compared to adults with
neither depression nor anxiety, the MCS scores were 10.35
points lower for those with depression and anxiety and 7.67
and 4.88 points lower for those with either depression or
anxiety, respectively (Table 2).
3.3. Economic Outcomes: Total Annual Healthcare
Expenditures. Adults with depression and/or anxiety also
had signiﬁcantly higher annual healthcare expenditures than
those with neither the condition (Table 3). Adults with
depression and anxiety had the highest expenditures at
$28,832 per person per year, followed by those with either
depression ($19,648) or anxiety ($16,990). After adjusting
for all other factors that may inﬂuence healthcare expenditures, results from recycled predictions showed that the
annual per-person mean healthcare expenditures were
$20,963 (95% conﬁdence interval (CI): $20,581–$21,329)
for those with both depression and anxiety and $16,861
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Table 1: Description of study sample by depression and anxiety categories among adults with comorbid diabetes and hypertension, using
pooled data from the 2013 and 2015 Medical Expenditure Panel Survey.

N

Wt%

Depression and
anxiety
N
Wt row%

4560

100.0

309

All
All

7.7

Depression
only
N
Wt row%
561

13.2

Anxiety
only
N
Wt row%
366

8.7

No depression/
anxiety
N
Wt row%
3324

p value

sig

<0.001

∗∗∗

<0.001

∗∗∗

<0.001

∗∗∗

<0.001

∗∗∗

70.4

Predisposing factors
Sex
Female
Male

2477
2083

50.1
49.9

227
82

10.9
4.4

368
193

16.5
10.0

227
139

10.3
7.0

1655
1669

62.3
78.6

Race/ethnicity
White
African-American
Latino
Others

1658
1267
1210
425

61.6
16.1
14.4
7.9

163
51
80
15

9.2
4.0
6.8
4.5

237
140
156
28

14.6
11.1
13.2
6.9

173
90
87
16

10.4
6.3
6.4
4.2

1085
986
887
366

65.8
78.6
73.6
84.4

Age groups
18–39 years
40–54 years
55–64 years
65–74 years
75 years or older

224
1016
1304
1165
851

4.4
19.9
26.8
28.6
20.3

21
96
98
65
29

10.5
10.3
8.6
7.3
3.7

30
121
191
152
67

15.5
13.2
16.0
13.8
8.4

23
77
98
92
76

8.7
8.3
8.8
8.2
9.4

150
722
917
856
679

65.3
68.1
66.6
70.8
78.5

Enabling factors
Marital status
Married
Not married
Education level†
<High school
High school
>HS

2352
2208

57.5
42.5

110
199

5.7
10.3

265
296

12.9
13.6

170
196

8.0
9.5

1807
1517

73.3
66.6

1301
1447
1751

19.1
34.2
46.7

74
110
121

6.0
8.9
7.5

158
174
223

11.4
12.9
14.2

106
126
131

9.3
9.2
8.1

963
1037
1276

73.3
69.0
70.2

0.186

Poverty status‡
Poor
Near poor
Middle income
High income

1014
1174
1321
1051

13.5
22.7
30.5
33.3

100
88
77
44

11.5
9.4
7.6
5.0

165
138
152
106

15.6
13.2
13.7
11.8

95
105
92
74

9.6
10.3
7.0
8.6

654
843
1000
827

2119
2067
374

57.0
37.3
5.7

100
193
16

5.8
10.8
6.1

230
294
37

13.2
14.0
9.1

161
190
15

8.3
9.8
4.6

1628
1390
306

<0.001

∗∗∗

72.7
65.4
80.1

Prescription insurance
Yes
No

∗∗∗

63.2
67.1
71.6
74.6

Insurance coverage
Private
Public
Uninsured

<0.001

0.020
1670
2890

44.7
55.3

79
230

5.9
9.1

182
379

13.8
12.8

128
238

8.6
8.7

1281
2043

∗

71.7
69.4

Need factors
Perceived physical health
Excellent/very good
Good
Fair/poor

1037
1642
1881

26.7
38.2
35.1

36
81
192

4.3
6.1
11.9

85
160
316

9.2
11.3
18.4

69
117
180

8.0
8.1
9.8

847
1284
1193

1979
1702
879

48.2
35.8
16.0

56
103
150

3.8
7.3
20.1

135
228
198

8.0
15.3
24.5

124
134
108

7.6
8.7
11.6

1664
1237
423

∗∗∗

<0.001

∗∗∗

78.5
74.6
59.8

Perceived mental health
Excellent/very good
Good
Fair/poor

<0.001

80.6
68.6
43.8
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Table 1: Continued.
All

N

Wt%

Depression and
anxiety
N
Wt row%

Depression
only
N
Wt row%

Anxiety
only
N
Wt row%

No depression/
anxiety
N
Wt row%

Multimorbidity
Yes
No

3179
1381

72.6
27.4

198
104

8.6
6.3

369
180

15.3
10.4

212
146

8.8
8.3

1729
1525

2240
757
1204
359

50.5
17.5
25.0
7.1

95
58
136
20

5.5
8.4
12.1
5.9

191
103
228
39

9.7
14.4
20.2
11.3

143
64
132
27

7.6
8.6
11.2
7.5

1811
532
708
273

sig

<0.001

∗∗∗

<0.001

∗∗∗

<0.001

∗∗∗

<0.001

∗∗∗

<0.001

∗∗∗

67.3
75.0

Pain interference
None/little
Moderate
A lot/extreme
Not reported

p value

77.3
68.6
56.6
75.3

Personal health practice
† ⁋

Obesity ,
Yes
No

2508
1955

57.3
42.7

198
104

8.6
6.3

369
180

15.3
10.4

212
146

8.8
8.3

1729
1525

67.3
75.0

Current smoker
Yes
No
Not reported

578
3553
429

12.2
79.2
8.6

77
214
18

12.8
7.1
5.5

103
415
43

21.0
12.4
9.7

49
281
36

7.7
8.7
9.1

349
2643
332

58.5
71.7
75.7

Exercise ≥ 5 times/week†
Yes
No

1584
2938

34.7
65.3

77
229

6.1
8.5

154
402

10.1
14.9

99
266

6.6
9.8

1254
2041

77.2
66.8

External environment
Region
Northeast
Midwest
South
West

0.027
740
800
2011
1009

17.2
22.0
42.6
18.3

76
69
109
55

11.1
8.9
5.7
7.6

99
106
250
106

12.7
13.0
13.9
12.4

56
80
166
64

8.1
10.2
8.7
7.2

509
545
1486
784

∗

68.0
67.9
71.7
72.8

Note: study sample included adults (≥18 years old) with comorbid diabetes and hypertension who were alive in the observation year (2013/2015). Wt%:
weighted percentages; Wt row%: weighted row percentages; Sig.: statistical signiﬁcance level. †Some groups with missing data were not reported here due to
small cell size (<10). ‡Poverty status was calculated from the annual family income and family composition using the federal poverty line (FPL). Poor was
deﬁned as <100% FPL; near poor was deﬁned as >100% FPL and <199% FPL; middle income was deﬁned as >200% FPL and <399% FPL; high income was
deﬁned as >400% FPL. ⁋Obesity was deﬁned as body mass index ≥ 30.0. ∗ p < 0 05; ∗∗ 0 001 < p < 0 01; ∗∗∗ p < 0 001.

(95% CI: $16,533–$17,155) and $14,735 (95% CI:
$14,466–$14,992) for those with either depression or anxiety.
The expenditures in these three groups were all signiﬁcantly
higher than the group with neither condition, with an incremental expenditure of $8709 (95% CI: $8550–$8861), $4607
(95% CI: $4523–$4687), and $2481 (95% CI: $2436–$2525),
respectively (Table 3).
Similar results were found for analyses on third-party
expenditures and out-of-pocket (OOP) spending (Table 3).
For instance, third-party payers spent an excess of $9132
(95% CI: $8956–$9304) annually among adults with both
depression and anxiety than those with neither condition.
Furthermore, the former group also had $399 (95% CI:
$393–$406) more OOP spending than the latter group.

without these two conditions (Table 4). Speciﬁcally, approximately one-third (34.0%) of those with both depression and
anxiety had high OOP burden versus 18.3% of those with
neither the conditions. Results from unadjusted and adjusted
logistic regressions consistently indicated that adults having
depression and anxiety were more likely to suﬀer from high
OOP burden as compared to those with neither the conditions. However, we did not observe any signiﬁcant association between either condition alone (depression or anxiety)
and high OOP burden after adjusting for all the predisposing
factors, enabling factors, need factors, personal health practices, and external environment (Table 4).

3.4. Economic Outcomes: OOP Spending Burden. We found
signiﬁcantly higher percentages of adults with depression
and/or anxiety bearing a high OOP spending burden (i.e.,
spending 10% or more of income on healthcare) than those

This study comprehensively evaluated the humanistic and
economic burden associated with depression and anxiety,
alone and together, among a nationally representative sample
of adults with comorbid diabetes and hypertension. Our

4. Discussion
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Table 2: Unadjusted and adjusted coeﬃcients for depression and anxiety categories from ordinary least square (OLS) regressions on physical
component summary (PCS) and mental component summary (MCS) scores among adults with comorbid diabetes and hypertension, using
pooled data from the 2013 and 2015 Medical Expenditure Panel Survey (MEPS).

MCS
Mean (SE)
40.45 (0.94) ∗∗∗

p value

Depression and anxiety

Unadjusted means and SE
PCS
Mean (SE)
p value
∗∗∗
37.27 (0.96)
<0.001

Depression only

37.02 (0.97) ∗∗∗

43.76 (0.71) ∗∗∗

<0.001

∗∗∗

<0.001

38.38 (1.04)

Anxiety only
No depression/anxiety (reference group)

Depression and anxiety

∗

<0.001
0.016

40.92 (0.34)

46.96 (0.78)

<0.001

52.8 (0.23)

Parameter estimates and SE from multivariable OLS regressions†
PCS
MCS
Beta (SE)
p value
Beta (SE)
−10.35 (0.91) ∗∗∗
−0.68 (0.87)
0.432

Depression only

−1.37 (0.83)

0.098

−7.67 (0.66) ∗∗∗

Anxiety only

0.01 (0.80)

0.987

−4.88 (0.74) ∗∗∗

p value
<0.001
<0.001
<0.001

No depression/anxiety (reference group)
Note: the analytic sample consisted of adults (>18 years) with comorbid diabetes and hypertension who were alive and eligible for the self-administered
questionnaires of MEPS in the observation year (2013/2015). SE: standard error of the mean; Beta: parameter estimates from multivariable OLS regressions.
†
Covariates included in the multivariable OLS regressions included predisposing factors (sex, age groups, and race/ethnicity), enabling factors (marital
status, education level, poverty status, health insurance coverage, and prescription drug insurance coverage), enabling factor (presence/absence of other
chronic conditions, pain interference), personal health practice (obesity, smoking status, and exercise level), and external environment (region). Pain
interference was not included in the regression on PCS scores because it was used in the computation of PCS scores with heavy weights. ∗ p < 0 05;
∗∗
p < 0 01; ∗∗∗ p < 0 001.

results revealed that a substantial proportion of adults with
comorbid diabetes and hypertension suﬀered from depression and/or anxiety. Some subgroups such as females, individuals with low socioeconomic status, current smokers,
and those with severe pain were more vulnerable than others
to be aﬀected. Adding regular check-ups for mental health to
diabetes management for these subgroups may help prevent
the development of depression or anxiety.
Our study ﬁndings showed that depression and anxiety,
either alone or together, were associated with poorer quality
of life relative to mental health, but not physical health,
among adults with comorbid diabetes and hypertension. It
is expected that individuals with mental health diagnoses
perceived poorer mental health. Although previous literature
suggested that depression could impact physical health [30],
we did not observe such association after adjusting for all
the predisposing factors, enabling factors, need factors,
personal health practice, and the external environment.
We speculated that adults with diabetes and hypertension
perceived the role limitations and impaired functional status
aﬀected by emotional problems rather than physical
suﬀerings. It is also possible that they received more medical
attention to physical symptoms than mental problems from
healthcare providers. Results from the National Comorbidity Survey Replication indicated that 60% of adults
with a recent mental health condition did not receive care
from healthcare professional [31]. Removing barriers to
seeking mental healthcare (i.e., mental health stigma)
and increasing access to mental health services are pivotal
to improve the quality of life for patients with comorbid
diabetes and hypertension.

In addition to impairments in quality of life, adults with
comorbid diabetes and hypertension also born excess economic burden from depression and anxiety, especially when
both conditions occurred. Li and colleagues reported that
almost one-fourth of adults with diabetes spent considerable
proportion (>10%) of family income for healthcare [32]. The
presence of comorbid depression and anxiety may expose
more diabetes patients and their families to ﬁnancial diﬃculties. Such excess spending burden may come from paying for
behavioral health interventions, which have relatively low
reimbursement rates. Lifting restrictions and increasing
reimbursement rates for behavioral health services can
enable more diabetes patients to aﬀord the care needed for
their overall well-being. Not only patients but also healthcare
payers such as Medicare, Medicaid, and private insurance
companies have signiﬁcantly higher costs due to depression,
anxiety, and the combination of these two. We estimated that
depression and anxiety together accounted for an excess
of $14.3 billion medical expenditures (2015 USD) for
third-party payers annually. The new payment model for
behavioral health services implemented by the Centers
for Medicare and Medicaid Services may be promising
in reducing costs for both patients and payers [33].
Like any other research study, our ﬁndings should be
interpreted along with the study strengths and limitations.
We believe this to be the ﬁrst study that comprehensively
examined the humanistic and economic burden of depression and anxiety among adults with comorbid diabetes and
hypertension in a nationally representative sample. Also,
our study utilized data that allows for adjustment of a comprehensive list of confounders. The recycled predictions
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Table 3: Unadjusted and adjusted annual per-person mean healthcare expenditures (2015 US$) by depression and anxiety categories among
adults with comorbid diabetes and hypertension, using pooled data from the 2013 and 2015 Medical Expenditure Panel Survey.
Adjusted mean†
Mean
(95% CI)‡, $

Unadjusted mean
Mean
(SE), $

N

Depression and anxiety

309

All payers
28,832.15 (5963.66) ∗∗
20,962.68 (20,580.69–21,328.80)

Depression only

559

19,648.34 (1,542.8) ∗∗∗
∗∗

Anxiety only

366

16,990.31 (2008.43)

No depression/anxiety

3256

11,543.4 (448.52)

Depression and anxiety

309

8708.81 (8550.11–8860.90)

16,860.66 (16,553.42–17,155.13)

4606.78 (4522.84–4687.24)

14,735.14 (14,466.63–14,992.49)

2481.26 (2436.05–2524.60)

12,253.88 (12,030.58–12,467.89)

(reference group)

Third-party payers
27,009.6 (5928.43) ∗∗
20,396.77 (20,003.49–20,782.35)
17,844.71 (1436.02)

∗∗∗

Adjusted incremental†
Mean
(95% CI)‡, $

9132.19 (8956.11–9304.83)

Depression only

559

15,659.59 (15,357.65–15,955.62)

4395.01 (4310.27–4478.09)

Anxiety only

366

15,236.58 (1996.7) ∗

13,273.26 (13,017.34–13,524.18)

2008.69 (1969.96–2046.66)

No depression/anxiety

3256

10,420.07 (445.14)

11,264.58 (11,047.38–11,477.53)

(reference group)

Out-of-pocket
Depression and anxiety

309

1822.54 (207.53) ∗∗∗

1382.75 (1361.19–1405.12)

399.31 (393.08–405.77)

Depression only

559

1803.64 (236.02) ∗∗

1364.25 (1342.98–1386.32)

380.81 (374.88–386.98)

1312.70 (1292.23–1333.94)

329.26 (324.12–334.59)

983.44 (968.10–999.35)

(reference group)

Anxiety only

366

No depression/anxiety

3256

1753.73 (231.31)

∗∗

1123.33 (41.17)

Note: the analytic sample consisted of adults (>18 years) with comorbid diabetes and hypertension who were alive and had positive expenditures in the
observation year (2013/2015). All the expenditures were converted to 2015 US dollars using the consumer product index from the US Bureau of Labor
Statistics. SE: standard error of the mean. †The adjusted annual per-person mean/incremental healthcare expenditures were obtained from recycled
predictions based on the estimates of generalized linear model (GLM) with log link function and gamma distribution. Covariates adjusted in the GLM
included predisposing factors (sex, age groups, and race/ethnicity), enabling factors (marital status, education level, poverty status, health insurance
coverage, and prescription drug insurance coverage), enabling factor (presence/absence of other chronic conditions, pain interference), personal health
practice (obesity, smoking status, and exercise level), and external environment (region). ‡Conﬁdence intervals are based on 2000 bootstrap replications
using the percentile method. ∗ p < 0 05; ∗∗ p < 0 01; ∗∗∗ p < 0 001.

Table 4: Unadjusted and adjusted association between depression and anxiety categories and high out-of-pocket (OOP) spending burden
among adults with comorbid diabetes and hypertension, using pooled data from the 2013 and 2015 Medical Expenditure Panel Survey.
Bivariate association between depression and anxiety categories and high OOP spending burden
High burden†
Not high burden
N
N
Wt row%
Wt row%
p value
Depression and anxiety

90

34.0

219

66.0

Depression only
Anxiety only
No depression/anxiety

158
96
650

28.2
23.5
18.3

403
270
2674

71.8
76.5
81.7

OR
Depression and anxiety
Depression only
Anxiety only
No depression/anxiety

2.26
1.72
1.34

Logistic regressions on high OOP spending burden†
Unadjusted model
95% CI
Sig.
AOR
(1.66–3.07)
(1.28–2.32)
(1.04–1.74)

∗∗∗
∗∗∗
∗

<0.001

Adjusted model‡
95% CI

1.55

(1.06–2.25)

1.25

(0.91–1.70)

1.03

(0.77–1.38)

Sig.
∗∗∗

Sig.
∗

(reference group)

Note: the analytic sample consisted of adults (>18 years) with comorbid diabetes and hypertension who were alive and had positive expenditures in the
observation year (2013/2015). Wt row%: weighted row percentages; Sig.: statistical signiﬁcance level; OR: odds ratio; AOR: adjusted odds ratio; 95% CI: 95%
conﬁdence interval. †OOP spending burden was measured by the percentage of household income spent on healthcare. It was calculated by dividing OOP
spending by household income. High OOP spending burden was deﬁned as 10% or more. ‡Covariates adjusted in the logistic regression included
predisposing factors (sex, age groups, and race/ethnicity), enabling factors (marital status, education level, poverty status, health insurance coverage, and
prescription drug insurance coverage), enabling factor (presence/absence of other chronic conditions, pain interference), personal health practice (obesity,
smoking status, and exercise level), and external environment (region). ∗ p < 0 05; ∗∗ p < 0 01; ∗∗∗ p < 0 001.
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provide realistic estimates of healthcare expenditures for a
typical diabetes patient. Such estimates can be better comprehended by policymakers than parameter estimates from conventional regression analyses. However, there are limitations
as well. First, the study results may subject to recall and social
desirability bias due to the self-reported nature of the MEPS
data. Second, there might be misclassiﬁcation bias from
undiagnosed depression/anxiety, leading to underestimation
of the disease burdens. Third, the diagnostic codes and clinical classiﬁcation codes provided by the MPES do not allow
us to further examine the burden of anxiety and depression
on diﬀerent types of diabetes and/or hypertension. Also, we
could not evaluate the duration and severity of diabetes and
hypertension from MEPS data. Future studies considering
these factors are warranted to conﬁrm our ﬁndings. Finally,
the cross-sectional design of our study may limit the ability
to demonstrate causality.

5. Conclusions
In summary, the present study indicated that depression and
anxiety, especially the combination of these two conditions,
are associated with signiﬁcant impairments in quality of life
and excess economic burden for patients with comorbid diabetes and hypertension. The burden estimates can be used as
benchmarks to evaluate future diabetes management programs. Our ﬁndings highlight the needs for timely screening
and early interventions that could help prevent anxiety and/
or depression among adults with comorbid diabetes and
hypertension to reduce their clinical, humanistic, and
economic burden. Furthermore, it is necessary to integrate
mental healthcare into diabetes management to improve
the quality of life for adults with comorbid diabetes and
hypertension. Innovative payment models that encourage
collaboration among primary care providers, diabetes specialists, and mental health professionals are needed to reduce
healthcare costs for both patients and healthcare payers.
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